throbber
Current
`
`cancer drug targets.
`DUP
`C‘ General Collection
`
`<
`1
`:' 1 L
`R
`
`~
`~—u‘ -
`1
`7///l'l1\\‘\\\
` A
`
`V
`
`'
`J-
`
`
`
`
`='
`7’-7
`
`.
`
` 1,
`
`
`
`
`
`..___.:rA“__Q_f__‘
`
`
`~-2:ii‘*-—7~‘;~“A3,,
`....
`
`I
`
`‘
`
`‘V
`
`‘
`
`1
`
`1‘
`
`V
`
`.
`
`k
`
`I
`
`.‘uvnnvsAv~.t«Iwl@A‘.!'Mll5f
`
`1
`
`‘
`
`V
`
`1
`
`'
`
`1
`
`L
`
`'
`
`1
`
`1
`Thi5 maT,«e,ri,al was Efvpaiéd
`
`’
`
`_.~L,.
`
`WJ";l£zE1iJ3;£31:w}
`Par Pharm., Inc.
`Exhibit 1 1 03
`
`Case lPR201 6-00084
`
`Par Pharm., Inc. v. Novartis AG
`
`Ex. 1103-0001
`
`Ex. 1103-0001
`
`

`
`Aims and Scope
`Current Cancer Drug Targets aims to cover all the latest and outstanding developments in
`the medicinal chemistry, pharmacology, molecular biology, genomics and bioclicmistry of
`contemporary molecular drug targets involved in cancer e.g. disease specific proteins,
`receptors, enzymes, genes.
`Each issue of the journal contains a series oftimely in—deptl1 reviews written by leaders in the
`field covering a range of current topics in drug targets involved in cancer.
`As the discovery, identification, characterization and validation of novel human drug targets
`for anti—cancer drug discovery continties to grow, this Journal will be essential reading for all
`pharmaceutical scientists involved in drug discovery and development.
`
`
`Multiple Journal Slll)SCl‘l[)(l()IlS & Global Onlilie Licenses
`For multiple journal subscriptions, possible discounts and global online licenses please contact our special sales
`department at
`ii-mail: subseriptions@bcntham.org
`
`/lilvertising
`
`To place an advertisement in this journal please contact the advertising department at l3—mail: ads@bentliam.org
`
`Jrmrlml Sample Copies
`A free online sample issue can be viewed at the journal‘s intcrnct homepage. Alternatively a free print sample issue may
`be requested, please send your request to 13-mail: sainple.copy@bentham.org
`
`Copyright © 2004 Bentham Science I’ublishers Ltd.
`
`is a condition of this publication that manuscripts submitted to this journal have not been published and will not be
`it
`simultaneously submitted or published elsewhere. By submitting a manuscript,
`the authors agree that the copyright for
`their article is transferred to the l’ublisher if and when the article is accepted for publication. The copyright covers the
`exclusive rights to reproduce and distribute the article,
`including reprints, photographic reproductions, microform or
`any other reproduction of similar nature, and translations. All rights reserved: no part of this publication may be
`reproduced, stored in a retrieval system, or transmitted in any form or by any means, on-line, mechanical, photocopying,
`recording or otherwise, without the prior written permission ol‘ the l’ublisher.
`
`l’/zotocopying Iliforlriatiolzfor Users in the USA
`is
`/\uthorization to photocopy items for internal or personal use, or the internal or personal use of specific clients,
`granted by Bentham Science Publishers Ltd. for libraries and other users registered with the Copyright Clearance Center
`tCCC) ’l'i'ansaetional Reporting Services, provided that the appropriate fee of USES 45.00 per copy per article is paid
`directly to Copyright Clearance Center, 222 Rosewood Drive, Danvcrs M/\ 01923, US/\. Refer also to www.copyright.coin
`l’lmt0c0pying Infarnmrirm for Users Outside the USA
`for private
`Bentham Science Pnblisliers Ltd. grants authoi'i'/.ation for
`individuals to photocopy copyright material
`research use, on the sole basis that requests for such use are referred directly to the requestor's local Reproduction Rights
`Organization (RRO). The copyright fee is USS 45.00 per copy per article exclusive of any charge or fee levied. In order to
`contact your local RRO. please contact the international l’ederation of Reproduction Rights Organizations (IFRRO), Rue
`du Prince Royal 37, 13-1050 Brussels, Belgium; Tel: +32 2 551 08 9‘); Fax: +32 2 S51 ()8 ‘)5; E-mail: sccretariat@il'rro.be
`'l‘his aiithori/.ation does not extend to any other kind of copying by any means,
`in any form, and for any purpose other
`than private research tise.
`The ltcin—Fee Code for this publication is: I568-0096/04 $45.0() + .00
`()nli/ie /lrticles
`
`This ptiblieation is available onlinc from lngcnta at www.ingenta.coin Individual articles are also available for sale online
`via lnfotricve at ww\v.infotrievecoin or from lngenta at \vww.ingenta.coni
`
`Permissimz for Other Use
`The l’ublishcr's consent does not extend to copying for general distribution, for promotion, for creating new works, or for
`resale. Specific permission intist be obtained from the Publisher for such copying. Requests must be sent
`to the
`permissions department at
`ll-mail: permission@benthani.org
`
`I)iselaimer
`
`its staff or members of the editorial board for any
`No responsibility is assumed by Bentham Science Publishers Ltd.,
`injury and/or damage to persons or property as a inattci' of products liability, negligence or otherwise, or from any use or
`operation of any methods, products instruction, advertisements or ideas contained in this publication/_journal. Any
`dispute will be governed exclusively by the laws of the U./\.l£. and will be settled exclusively by the competent Court at
`the city of Dubai, U./\.l;'.
`
`This materia l w‘as.»:>npiEd
`atthle NLM and may be
`Subject US£”ei:sp~'sgright Laws
`
`

`
`Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
`
`Current Cancer Drug Targets, 2004, 4, 621-635
`
`621
`
`Ravi D. Rao, Jan C. Buckner and Jann N. Sarkaria*
`
`Department of Oncology, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905, USA
`Abstract: Highly specific signal transduction inhibitors are being developed as anti-cancer agents against an
`array of molecular targets, with the promise of increased selectivity and lower toxicity than classic cytotoxic
`chemotherapy agents. Rapamycin and its analogues are a promising class of novel therapeutics that specifically
`inhibit signaling from the serine-threonine kinase, mammalian target of rapamycin (mTOR). mTOR is a key
`intermediary in multiple mitogenic signaling pathways and plays a central role in modulating proliferation and
`angiogenesis in normal tissues and neoplastic processes. Rapamycin potently inhibits T-cell proliferation, and
`is approved for clinical use as an immuno-suppressant following kidney transplantation. Hyperactivation of
`mTOR signaling has been implicated in tumorigenesis, and promising pre-clinical studies in several tumor
`types suggest that the anti-proliferative and anti-angiogenic properties of rapamycin may be useful in cancer
`therapy. These studies have led to several clinical trials evaluating the safety and efficacy of rapamycin analogs
`in cancer therapy. The goal of this article is to review the mechanism of action of rapamycin as an anti-cancer
`agent, and to review the clinical experience with rapamycin and rapamycin analogs as immunosuppressive and
`anti-neoplastic therapeutic agents.
`Key words: Rapamycin, CCI-779, temsirolimus, RAD-001, everolimus, AP23573, sirolimus, cancer, cytostatic anti-cancer
`drugs, mTOR, renal transplant, immunosuppressive agents.
`
`INTRODUCTION
`
`Rapamycin and its analogues are novel, molecularly
`targeted drugs that are being developed as anti-cancer agents.
`The parent compound, rapamycin (Sirolimus, Rapamune;
`Wyeth-Ayerst) is approved by the Food and Drug
`Administration (FDA) for the prevention of allograft
`rejection following renal
`transplantation, and for
`incorporation into drug-eluting stents to prevent re-stenosis
`following coronary angioplasty. Experience in the transplant
`setting suggests that long-term use of this agent is safe and
`well tolerated. Rapamycin analogues with more favorable
`pharmacokinetic properties are currently being developed as
`anti-cancer drugs. Rapamycin and its analogs inhibit the
`signaling activity of the serine-threonine protein kinase,
`mammalian target of rapamycin (mTOR). mTOR functions
`downstream from multiple growth factor receptor tyrosine
`kinases to promote cell growth and proliferation. Key
`downstream targets of mTOR include p70S6 kinase and
`eukaryotic initiation factor 4E-binding protein (4EBP1),
`which modulate the translation of select mRNA transcripts
`that ultimately impact on cell growth and cell cycle
`progression. More recent data have linked mTOR signaling
`with the cellular response to hypoxia and the expression of
`vascular endothelial growth factor (VEGF), which suggests
`that mTOR may be an important mediator of tumor
`angiogenesis. In tumors that are reliant on mTOR signaling,
`disruption of these key signaling pathways by rapamycin
`results in cell cycle arrest and inhibition of angiogenesis,
`and these effects may account for the anti-neoplastic
`activities of mTOR inhibitors seen in multiple tumor types.
`Based on promising pre-clinical studies, rapamycin and its
`analogs currently are being tested as anti-neoplastic agents,
`
`*Address correspondence to this author at the Department of Oncology,
`Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905,
`USA; E-mail: sarkaria.jann@mayo.edu
`
`both given alone or in combination with conventional cancer
`therapies. In this review, the biology of mTOR signaling
`and the cellular pharmacology of mTOR inhibition will be
`discussed as will the clinical development of mTOR
`inhibitors.
`
`History
`
`Rapamycin is a macrocyclic lactone antibiotic that was
`first isolated from the bacterium Streptomyces hygroscopicus
`found in soil samples taken from Easter Island (called ‘Rapa
`Nui’ by its native inhabitants; hence the name ‘Rapamycin’).
`After its isolation and purification, studies revealed that
`rapamycin was a potent anti-fungal agent and an effective
`immunosuppressant[1]. Subsequent studies demonstrated
`that rapamycin inhibited proliferation in several tissues
`including IL-2 stimulated T-cells, vascular endothelium,
`smooth muscle, and tumor cells. These observations
`prompted the development of rapamycin and its analogs as
`immunosuppressive agents, inhibitors of vascular re-
`occlusion and as anti-cancer agents.
`Rapamycin and three analogs, CCI-779, RAD-001 and
`AP23573, have been developed for human use (Fig. (1)).
`Among
`these, only rapamycin (Sirolimus, Wyeth
`Pharmaceuticals) is currently approved, for preventing
`kidney allograft rejection following renal transplantation and
`in drug-eluting stents to reduce the incidence of re-stenosis
`following coronary artery angioplasty. CCI-779
`(Temsirolimus, Wyeth Pharmaceuticals) is an ester of
`rapamycin, with superior oral bioavailability compared to
`the parent compound rapamycin. This drug is available in
`oral and intravenous formulations, and clinical development
`of this drug is well underway with several phase II and III
`trials being conducted. RAD-001 (Everolimus, Novartis
`Pharmaceuticals) is an orally available hydroxyethyl
`derivative of rapamycin developed by Novartis for
`applications in the transplant, cardiovascular and oncological
`
`1568-0096/04 $45.00+.00
`
`© 2004 Bentham Science Publishers Ltd.
`
`

`
`622 Current Cancer Drug Targets, 2004, Vol. 4, No. 8
`
`Sarkaria et al.
`
`R
`
`H
`
`O
`
`H
`
`O
`
`CH3
`
`CH3
`O
`
`OH
`
`O
`
`Rapamycin, R =
`
`OH
`
`RAD001, R =
`
`O
`
`O
`
`OH
`
`CCl-779, R =
`
`O
`
`OH
`
`OH
`
`CH3
`
`CH3
`
`CH3
`
`CH3
`
`O
`
`CH3
`
`CH3
`
`H
`
`O
`
`H
`
`N
`
`O
`
`O
`
`O
`
`HO
`H3C
`CH3
`Fig. (1). Structure of rapamycin and rapamycin derivatives.
`
`O
`
`settings, and clinical testing for all these indications are
`ongoing. The newest mTOR inhibitory agent to be
`developed
`for clinical use
`is AP23573
`(Ariad
`Pharmaceuticals). Early phase I clinical trials with this
`agent, which is also an analog of rapamycin, are now
`underway.
`
`BIOLOGY OF mTOR
`
`mTOR is a serine-threonine-directed kinase that belongs
`to the family of phosphatidyl-inositol 3-kinase-related
`kinases (PIKK). All members of this PIKK family contain a
`C-terminal kinase domain that shares significant homology
`with that of the phosphatidyl-inositol 3-kinase (PI3K); other
`members of this family include ataxia telangiectasia mutated
`(ATM), ATM and Rad3 related (ATR) and DNA-dependent
`protein kinase (DNA-PK) [2,3]. These latter 3 kinases play
`key roles in orchestrating DNA damage checkpoint responses
`and DNA repair [4]. In contrast, mTOR monitors
`intracellular nutrient and energy availability and promotes
`cell growth and proliferation following mitogenic stimuli,
`dependent upon the availability of requisite nutrients [5].
`Rapamycin is a highly specific inhibitor of mTOR
`function. Rapamycin is unable to bind directly to mTOR,
`but forms a complex with the immunophilin, 12 kDa
`FK506-binding protein (FKBP12; FK-506 is an unrelated
`immunosuppressant); it is this drug-protein complex that
`binds to mTOR through an FKBP12-rapamycin binding
`(FRB) domain[6]. The FRB domain is adjacent to the
`kinase domain in mTOR and formation of this tri-molecular
`complex markedly attenuates downstream signaling from
`mTOR. Interestingly, rapamycin treatment does not inhibit
`mTOR catalytic kinase activity directly, since
`autophosphorylation of mTOR is unaffected by rapamycin
`treatment. Instead, binding of the FKBP12/rapamycin
`complex is thought to prevent interaction of mTOR with its
`kinase substrates and thus prevent downstream signaling [7].
`The interaction of the rapamycin/FKBP12 complex with
`mTOR is highly specific and is so stable that inhibition of
`mTOR by rapamycin is essentially irreversible. The cellular
`and biochemical effects of rapamycin are generally believed
`to result exclusively from inhibition of mTOR signaling
`[8,9].
`
`The mTOR signaling network (Fig. (2)) is important for
`driving cell growth and proliferation in multiple tumor
`types. Several receptor tyrosine kinases (RTKs), including
`the epidermal growth factor receptor (EGFR), platelet-
`derived growth factor receptor (PDGFR) and insulin-like
`growth factor (IGFR) can activate PI-3 kinase activity,
`which, in turn, phosphorylates phosphatidylinositol (PI) on
`the D-3 position [10]. The resulting accumulation of
`phosphatidylinositol-3, 4, 5-triphosphate on the cytoplasmic
`surface of the plasma membrane leads to activation of a
`number of kinase signaling pathways including that
`regulated by protein kinase B (PKB, Akt). Akt stimulates
`mTOR function both through direct phosphorylation of a
`negative regulatory domain within mTOR [11] as well as
`through its effects on the tuberous sclerosis complex-2
`(TSC2) protein [12-15]. TSC2, in a complex with tuberous
`sclerosis complex-1 (TSC1) protein, functions as a GTPase-
`activating protein towards the Rheb1 GTPase. Akt-mediated
`phosphorylation of TSC2 disrupts the TSC1/TSC2 complex
`and relieves inhibition of Rheb1 activity; activated Rheb1
`then can stimulate mTOR phosphorylation and signaling
`(see Fig. (2)) [16-19]. The inhibitory effects of TSC2 on
`mTOR activity are stimulated in nutrient deprived
`conditions by activation of LKB-1, which signals through
`AMP-activated protein kinase (AMPK) to enhance TSC2
`activity [20,21]. Signaling from mTOR also is regulated by
`association with Raptor, which probably functions as a
`scaffolding protein to promote transient association and
`phosphorylation of downstream
`targets
`[22,23].
`Collectively, these data highlight the idea that mTOR
`functions within a molecular complex of multiple proteins
`that regulate its activity [24].
`PI3K-mediated activation of Akt is normally opposed by
`the lipid phosphatase PTEN (phosphatase and tensin
`analogue), which dephosphorylates phosphatidylinositol at
`the D-3 position. Deletion or mutation of the gene encoding
`this tumor suppressor protein commonly occurs in multiple
`tumor types and results in constitutive activation of PI3K-
`dependent signaling pathways that include Akt and activated
`Ras as signaling mediators. Consistent with the potential
`role of the Akt/mTOR signaling pathway in tumorigenesis,
`overexpression of activated Akt and activated Ras in glial
`progenitor cells leads to formation of GBM-like tumors in a
`
`

`
`Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
`
`Current Cancer Drug Targets, 2004, Vol. 4, No. 8 623
`
`Fig. (2). The mTOR signaling network.
`
`transgenic mouse model [25], and these tumors are
`exquisitely sensitive to treatment with rapamycin. Germ-line
`inherited deficiencies in PTEN, TSC or LKB-1 result in
`Cowden’s disease, Tuberous Sclerosis and Peutz-Jeghers
`syndrome, respectively, which are all characterized by the
`development of multiple benign hamartomas. Loss-of-
`function in any one of these three proteins results in
`hyperactivation of mTOR signaling, and this presumably
`accounts for the development of the characteristic
`hamartomatous lesions. Thus, constitutive activation of
`mTOR signaling can be an important contributor to
`tumorigenesis in both benign and malignant tumors.
`
`mTOR-Dependent Signaling Pathways
`
`mTOR signals downstream to multiple protein targets:
`p70 S6 kinase (p70S6K), eukaryotic translation initiation
`factor 4E binding protein (4E-BP1), and the hypoxia-
`inducible transcription factor, HIF-1α. These 3 well-
`characterized downstream signaling targets have been
`implicated in control of hypoxia- and mitogen-induced
`tumor proliferation and disruption of these pathways may
`play an important role in the anti-tumor effects of
`rapamycin. In the sections below, we will describe the
`potential links between the anti-tumor effects of mTOR
`inhibitors and disruption of downstream signaling to
`p70S6K, 4EBP1 and HIF-1α in more detail.
`
`p70S6K
`
`mTOR regulates translation of select mRNA transcripts
`containing 5’-terminal oligopyrimidine (5’TOP) tracts
`
`through phosphorylation of p70S6K. Following PI3K-
`dependent phosphorylation of residues within an auto-
`inhibitory domain, mTOR regulates the phosphorylation of
`Thr-389 [26]. Modification of this residue is essential for
`subsequent phosphorylation of other residues within the
`activation loop of the kinase domain, which allows for full
`catalytic activity. After mitogen stimulation, activated
`p70S6K phosphorylates the S6 component of the 40S
`ribosomal subunit, and this promotes translation of mRNA
`containing 5’TOP [27]. Because transcripts for many
`ribosomal proteins and translation elongation factors contain
`this 5’TOP motif, rapamycin-mediated suppression of
`p70S6K activity may inhibit cell growth and proliferation
`by limiting ribosomal biogenesis and restricting protein
`synthesis capacity.
`
`4EBP1
`
`mTOR modulates protein translation initiation by
`regulating the assembly of the eukaryotic initiation factor 4F
`(eIF4F) complex on the 5’-methyl-GTP cap of mRNA
`transcripts. The eIF4F complex is a heterotrimer composed
`of the mRNA cap-binding protein eIF4E, a scaffolding
`protein eIF4G, and a helicase eIF4A (reviewed in [5]). This
`tripartite complex regulates the rate of cap-dependent protein
`translation by mediating the rate-limiting step of mRNA
`loading onto the small 40S ribosomal subunit. Formation of
`a functional eIF4F complex is controlled by the
`phosphorylation status of an eIF4E binding protein (4E-
`BP1). In nutrient- or growth factor-deprived cells, the
`association of hypophosphorylated 4E-BP1 with eIF4E
`blocks binding of eIF4G to the cap structure and inhibits
`
`

`
`624 Current Cancer Drug Targets, 2004, Vol. 4, No. 8
`
`Sarkaria et al.
`
`cap-dependent translation. In contrast, nutrient- or mitogen-
`induced phosphorylation of 4E-BP1 disrupts association
`with eIF4E and allows formation of a functional eIF4F
`complex [28,29]. 4E-BP1 is phosphorylated on at least 5
`serine or threonine sites, and these mitogen-induced
`modifications are regulated, in part, by mTOR. Several
`studies have suggested that mTOR directly phosphorylates
`all 5 sites on 4E-BP1 [30,31], while others have argued that
`direct mTOR phosphorylation of 2 of the sites (Thr-37 and
`Thr-46) serves as a priming event that allows subsequent
`phosphorylation of the other sites (Ser-65, Thr-70, and Ser-
`83) by other signaling pathways [32]. Rapamycin
`diminishes 4E-BP1 phosphorylation, prevents dissociation
`of 4E-BP1 from eIF4E, and results in inhibition of cap-
`dependent translation. Because translation is less efficient for
`transcripts with complex secondary structures, rapamycin
`preferentially inhibits translation of mRNA transcripts
`containing complex 5’ untranslated regions (UTR) [33].
`Transcripts with complex 5’UTRs whose translation is
`inhibited by rapamycin include key proteins involved in cell
`proliferation and angiogenesis, such as cyclin D1, ornithine
`decarboxylase and vascular endothelial growth factor
`(VEGF).
`
`HIF-1αααα
`
`Hypoxia induces the expression of multiple genes
`containing hypoxia response elements (HREs), and
`transcription from this response element is regulated
`primarily by the HIF-1 transcription factor. HIF-1 is a
`heterodimer composed of HIF-1α and HIF-1β. Under
`normoxic conditions, HIF-1 heterodimer levels are
`undetectable due to rapid degradation of HIF-1α subunit.
`The stability of HIF-1α is regulated through post-
`translational modification of an oxygen-dependent
`degradation (ODD) domain. In the presence of oxygen,
`prolyl hydroxylases modify two conserved proline residues
`(Pro-402 and Pro-564) within
`the ODD [34,35].
`Hydroxylation of these residues promotes HIF-1α
`association with the von Hippel Lindau-containing ubiquitin
`ligase complex and subsequent ubiquitin-mediated
`proteosomal degradation. Because molecular oxygen is
`required for catalysis of this reaction, hypoxic conditions
`prevent hydroxylation of the ODD, which results in
`stabilization of HIF-1α . Other transactivating post-
`translational modifications and dimerization with the HIF-1β
`subunit result in formation of an active HIF-1 transcriptional
`complex. HIF-1 drives expression of genes, such as VEGF,
`which contain HREs within their promoter region. The
`repertoire of hypoxia-inducible genes enables tumor or
`normal tissues to adapt to low oxygen environments and
`include genes involved in oxygen and glucose transport,
`glycolysis, growth-factor signaling, immortalization, genetic
`instability, invasion and metastasis, apoptosis and pH
`regulation [36].
`Signaling through the PI3K/mTOR pathway regulates
`HIF-1α expression and activity [37]. The link between PI3K
`signaling and HIF-1α activity was first established in Ras-
`transformed cells, where hypoxia-induced signaling to HIF-1
`was blocked by genetic or pharmacological inhibition of
`PI3K activity [38]. Subsequent studies have demonstrated
`that restoration of wild-type PTEN function, expression of a
`
`dominant-negative Akt construct, or treatment with
`rapamycin blocks hypoxia and mitogen-induced HIF-1
`signaling [39-41]. Moreover, a recent study demonstrated
`that rapamycin blocks both hypoxia-induced HIF-1α
`accumulation and transactivation, and that this effect of
`rapamycin is specifically due to pharmacological inhibition
`of mTOR [42]. Collectively, these data suggest the existence
`of a PI3K/Akt/mTOR signaling pathway that regulates HIF-
`1α expression, stability or activation.
`
`ANTI-TUMOR EFFECTS OF RAPAMYCIN
`
`The central role for mTOR in modulating cell
`proliferation in both tumor and normal cells and the
`importance of mTOR signaling for the hypoxic response
`suggests that rapamycin-based therapies may exert anti-
`tumor effects primarily through either inhibition of tumor
`cell proliferation or suppression of angiogenesis. Pre-clinical
`and early clinical results demonstrate that only a subset of
`tumors will respond to rapamycin-based therapies. In the
`following sections, we will review the pre-clinical efficacy
`data, the evidence supporting the anti-angiogenic and
`cytostatic properties of rapamycin, and discuss potential
`mechanisms of resistance to mTOR inhibition.
`Pre-clinical studies have demonstrated efficacy of
`rapamycin analogs and the parent compound in multiple
`tumor types. In the National Cancer Institute 60 tumor cell
`line panel, both rapamycin (NSC 226080) and CCI-779
`(NSC 683864) demonstrated growth inhibitory activity
`against a broad spectrum of tumors with a subset of
`leukemia, lung, brain, prostate, breast, renal and melanoma
`tumor cell lines being inhibited at low nanomolar
`concentrations (http://dtp.nci.nih.gov/). Early animal studies
`at the NCI and at Ayerst Research Laboratories demonstrated
`modest growth inhibitory properties of rapamycin in murine
`tumor models of B16 melanoma, P388 lymphocytic
`leukemia, EM ependymoblastoma, CD8F1 breast carcinoma,
`Colon 38, CX-1 and 11/A colon cancer models [43].
`Subsequent published studies have documented significant
`tumor growth inhibition with rapamycin or CCI-779
`treatment of DAOY medulloblastoma, U251 or SF295
`glioma, PC-3, DU-145, LAPC4, or LAPC9 prostate
`carcinoma, and Rh-18 rhabdomyosarcoma human tumor
`xenografts [44-47]. These data have provided the impetus for
`development of mTOR inhibitor therapy in a variety of
`tumor types.
`Treatment of tumor cells in vitro with rapamycin results
`in an accumulation of cells in the G1 phase of the cell cycle.
`Similarly, rapamycin treatment in tumor-bearing animals
`results in decreased tumor cell proliferation as indicated by
`BrdU labeling index [48]. At the molecular level, this drug-
`induced cell cycle arrest is associated with an accumulation
`of the cyclin-dependent kinase inhibitor, p27kip1, decreased
`expression of cyclinD1, and a corresponding decrease in
`phosphorylation of the retinoblastoma protein. CyclinD1
`mRNA contains a complex 5’UTR, and reduction in
`cyclinD1 levels presumably results from rapamycin-mediated
`inhibition of 4EBP1 phosphorylation and the resulting
`inhibition of eIF4F function. Likewise, the mRNA encoding
`for multiple oncogenes or proteins involved in DNA
`metabolism and S-phase progression contain complex
`
`

`
`Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
`
`Current Cancer Drug Targets, 2004, Vol. 4, No. 8 625
`
`5’UTRs and are regulated by mTOR [49]. Although
`rapamycin can induce apoptosis in select tumor models,
`rapamycin treatment typically slows tumor growth but does
`not induce tumor regression, suggesting that increased tumor
`cell loss through apoptosis or other mechanisms of cell
`death likely are not major contributors to drug effect in most
`tumors. Collectively, these data support the idea that
`rapamycin exerts a cytostatic effect on tumor cell growth.
`Rapamycin also has cytostatic effects on normal and
`tumor vasculature. As discussed above, mTOR plays an
`important role in modulating the cellular response to
`hypoxia through stabilization and activation of HIF-1α.
`HIF-1 drives expression of hypoxia-responsive genes, and
`these genes include those such as vascular endothelial
`growth factor (VEGF) that are important for tumor
`angiogenesis. Translation of VEGF mRNA also is regulated
`in an mTOR-dependent manner via its complex 5’UTR.
`Consistent with these mechanisms of regulation, treatment
`of tumor-bearing animals with rapamycin results in
`decreased expression of VEGF mRNA in tumors [50] and
`decreased circulating levels of VEGF protein [51]. VEGF
`drives endothelial proliferation through interaction with its
`cognate receptor tyrosine kinases, VEGF receptor 1 and 2,
`and these receptors can signal downstream through the
`PI3K/Akt pathway to mTOR. Thus, proliferation of smooth
`muscle and endothelial cells is inhibited by mTOR
`inhibition [52,53], and this effect is likely related to the
`efficacy of rapamycin-eluting stents in preventing vascular
`
`re-occlusion. In animal models, rapamycin inhibits tumor
`growth and neo-vascularization of CT-26 colon tumors
`grown in a dorsal skin-fold model and suppresses serum
`levels of VEGF in tumor bearing animals[51]. Thus the anti-
`angiogenic effects may contribute to the efficacy of mTOR
`inhibitors in cancer therapy.
`The anti-tumor effects of rapamycin therapies are likely
`secondary to both inhibition of tumor cell proliferation and
`inhibition of tumor angiogenesis. The relative contribution
`of these two effects in any given tumor may be difficult to
`delineate. However, pre-clinical and clinical data suggest that
`that only a subset of tumors will respond to rapamycin; one
`of the challenges will be to identify patients most likely to
`respond to this class of agents. Future studies delineating
`the relative contributions of the anti-proliferative and anti-
`angiogenic effects to the overall anti-tumor efficacy of
`rapamycin will be invaluable for identifying the relevant
`cellular targets that are responsible for the anti-tumor effects
`of rapamycin.
`
`COMBINATIONS OF MTOR ANTAGONISTS WITH
`OTHER ANTI-CANCER AGENTS
`
`Angiogenesis and tumor cell proliferation have been
`implicated as important mediators that can influence the
`efficacy of traditional cytotoxic cancer therapies; therefore,
`much research effort has focused on the evaluation of
`
`Fig. (3). Rapamycin enhances the efficacy of radiation in U87 xenografts. Nude mice with established U87 flank xenografts were
`randomized into four treatment groups: 1) placebo, 2) radiation only (4 Gy x 4), 3) rapamycin only (1 mg/kg), or 4) radiation and
`rapamycin. The tumor re-growth for each treatment group is shown. Data points represent the mean relative tumor volume ± SE.
`Treatment was initiated on Day 0 with the first injection of rapamycin (Rap). The schedule for Rap and radiation (RT) treatments is
`depicted below the x-axis. Highly similar results were obtained in two independent experiments. (Reproduced with permission,
`Cancer Res., 2002, 62, 7291-7297).
`
`

`
`626 Current Cancer Drug Targets, 2004, Vol. 4, No. 8
`
`Sarkaria et al.
`
`combinations of mTOR inhibitors with standard cancer
`therapies. Rapamycin potentiates cisplatin induced apoptosis
`in multiple cell lines including HL-60 leukemia cells and
`SKOV3 ovarian cancer cells [54]. Likewise, insulin-like
`growth factor-induced resistance to cisplatin in Rh30
`rhabdomyosarcoma cells can be reversed by rapamycin
`treatment [55]. Geoerger et al. demonstrated
`that
`combinations of rapamycin with either cisplatin or
`camptothecin provides additive growth inhibition in the
`rapamycin-sensitive DAOY medulloblastoma cell line but
`not in the rapamycin-resistant D283 cell line [46].
`Consistent with this in vitro data, CCI-779 therapy provides
`for additive tumor growth inhibition in animals when
`combined with doxorubicin or cisplatin in PC3 or DAOY
`xenografts, respectively [46]. Several other investigators
`have confirmed the in vitro effect of rapamycin on
`sensitizing cancer cells to chemotherapeutic agents such as
`adriamycin, VP-16, and cisplatin1 and hormonal therapies
`such as tamoxifen2 dexamethasone3, and the anti-estrogen
`ERA-9234. Rapamycin also has been combined with other
`molecularly targeted therapeutics. In our laboratory, we
`found that the combination of rapamycin with the EGFR
`inhibitor EKI-785 resulted in synergistic growth inhibition
`(unpublished data), and similar results were reported with
`the combination of RAD-001 and the VEGFR/EGFR
`inhibitor AEE7885. Likewise, rapamycin combined with the
`bcr/abl inhibitor Imatinib mesylate (Gleevec) provided
`synergistic growth inhibition of chronic myeloid leukemia
`(CML) cell lines6. Taken together, these data suggest that
`mTOR-dependent signaling may be important for resistance
`to chemotherapy-induced apoptosis and provides a rationale
`for
`the combination of rapamycin with specific
`chemotherapy agents.
`Rapamycin also can enhance the efficacy of radiation
`therapy. Based on significant pre-clinical and clinical data
`demonstrating that tumor proliferation during fractionated
`radiotherapy contributes to clinical radiation resistance
`
`1.Savaraj, N.; Wu, C.; Wangpaichitr, M.; Lampidis, T.; Robles, C.; Furst,
`A.; Feun, L. Circumvention of drug resistance in small cell lung cancer by
`mTOR inhibitor. Proc. Am. Assoc. Cancer Res. 2003, 44, 2nd ed., Abstract
`# 3704.
`2.deGraffenried, L.; Friedrichs, W.; Fulcher, L.; Silva, J.; Roth, R.;
`Hidalgo, M. The mTOR inhibitor, CCI-779, restores tamoxifen response in
`breast cancer cells with high Akt activity. Eur. J. Cancer 2002, 38(Suppl.
`7), Abstract # 528.
`3.Yan, H.; Shi, Y.; Frost, P.; Hoang, B.; Gera, J.; Lichtenstein, A. The
`mTOR inhibitor rapamycin sensitizes multiple myeloma cells to apoptosis
`induced by dexamethasone. Blood 2003, 102, Abstract # 3453.
`4.Zhang, T.; Sadler, T.; Annable, M.; Achilleos, P.; Frost, P.; Greenberger,
`L. Combination therapy for treating breast cancer using the antiestrogen,
`ERA-923 and the mTOR inhibitor, CCI-779. Proc. Am. Assoc. Cancer Res.
`2003, 44, 2nd ed., Abstract # 3715.
`5.Goudar, R.; Keir, S.; Hjelmeland, M.; Conrad, C.; Traxler, P.; Lane, H.;
`Wang, X.; Bigner, D. D.; Friedman, H. S.; Rich, J. N. Combination therapy
`of inhibitors of the epidermal growth factor/ vascular endothelial growth
`factor receptor 2 (AEE788) and the mammalian target of rapamycin
`(RAD001) offers improved glioblastoma tumor growth inhibition. EORTC-
`NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
`2003, Abstract # A88.
`6.Halbur, L.; Ly, S. C.; Ong, T. Inhibition of mTOR by Rapamycin
`Enhances Killing of CML Cells by Imatinib Mesylate and Overcomes
`Certain Forms of Imatinib R

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket